Zobrazeno 1 - 10
of 11
pro vyhledávání: '"John Jezorwski"'
Autor:
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups
Publikováno v:
HIV Research & Clinical Practice, Vol 21, Iss 6, Pp 151-167 (2021)
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Obje
Externí odkaz:
https://doaj.org/article/0075f5926758485aa79ac9cb573f7b85
Autor:
Bruce Rashbaum, Christoph D. Spinner, Cheryl McDonald, Cristina Mussini, John Jezorwski, Donghan Luo, Erika Van Landuyt, Kimberley Brown, Eric Y. Wong
Publikováno v:
HIV Research & Clinical Practice, Vol 20, Iss 1, Pp 24-33 (2019)
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/c
Externí odkaz:
https://doaj.org/article/2398a84fc10a4d59a8c3ed8590f56b34
Autor:
Sophia Gailhardou, Anna Skipetrova, Gustavo H Dayan, John Jezorwski, Melanie Saville, Diane Van der Vliet, T Anh Wartel
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004821 (2016)
A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2-16 years in Asia and Latin A
Externí odkaz:
https://doaj.org/article/4a9955c0bd7e4bf0bcf5d650f0e1b0a3
Autor:
John Jezorwski, Juan Jose Perez-Ruixo, Herta Crauwels, Carlos Perez-Ruixo, Oliver Ackaert, David McDougall
Publikováno v:
The AAPS Journal. 23
The single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg has undergone phase III studies AMBER (NCT02431247) and EMERALD (NCT02269917) in HIV-infected patients. An existing population pharmacoki
Autor:
Cheryl McDonald, Cristina Mussini, Donghan Luo, Eric Y Wong, Christoph D. Spinner, Kimberley Brown, John Jezorwski, Erika Van Landuyt, Bruce Rashbaum
Publikováno v:
HIV Research & Clinical Practice. 20:24-33
Background: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-wee...
Autor:
Erika Van Landuyt, Erkki Lathouwers, Christoph D. Spinner, Kimberley Brown, Aimee M. Wilkin, Gregory D Huhn, John Jezorwski, Amber, Mohsine El Ghazi, Emerald study groups, Bryan Baugh, Cristina Mussini
Publikováno v:
HIV researchclinical practice. 21(6)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). To describe a W
Autor:
Sandra De Meyer, Erika Van Landuyt, Bryan Baugh, Erkki Lathouwers, Shirley Weinsteiger, El Ghazi Mohsine, John Jezorwski, Anne Ghys
Publikováno v:
Journal of medical virologyREFERENCES. 93(6)
In AMBER and EMERALD, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg demonstrated high virological response and low virological failure (VF) through week 96. Week 96 resistance analyses are presented. Post-base
Autor:
Douglas Cunningham, D. Ward, Mamta K. Jain, Faiza Ajana, Magda Opsomer, Anita Rachlis, Sharon Walmsley, Frank A. Post, Anders Blaxhult, Amanda Clarke, M. J. Galindo, Marcel Stoeckle, P.-M. Girardy, Karam Mounzer, David Shamblaw, U. F. Bredeek, L. Bhatti, J. J. Eron, Andrew Ustianowski, Mar Gutierrez, John Jezorwski, Javier O Morales-Ramirez, Antonio Rivero, M.A. Johnson, Gatell Jm, Erika Van Landuyt, Stéphane De Wit, A. Wilkin, Laurent Cotte, Cheryl McDonald, D. Murphy, Cynthia Brinson, Romana Petrovic, Olayemi Osiyemi, J. de Vente, I. Poizot-Martin, Juan Berenguer, Robin Dretler, J. Bailey, B. Rashbaum, Moti Ramgopal, A. Scribner, Yazdan Yazdanpanah, Eric Florence, A. Piekarska, Brian Gazzard, Chloe Orkin, W. Halota, Gary Richmond, Jacques Reynes, C. Ricart, C. Lucasti, Ignacio Pérez-Valero, Jason Brunetta, S. Shafran, Daniel Podzamczer, Franco Antonio Felizarta, Claudia Martorell, F. Post, Peter Ruane, Edwin DeJesus, J. Portilla Sogorb, C. Orkin, K. Tashima, Federico Pulido, Bernard Vandercam, F. Pulido, José L. Casado, Christine Katlama, Kimberley Brown, J Gasiorowski, A. Witor, Joseph J. Eron, Brian Conway, Andri Rauch, Jose R. Arribas, Michel Moutschen, H. Olivet, A. Scarsella, Leo Flamholc, A. Horban, D. Cunningham, Ronald Nahass, Félix Gutiérrez, G. Huhn, W.K. Henry, A. Thalme, S De Wit, Jan Fehr, Debbie Hagins, José Antonio Iribarren, J.-M. Molina, S. Henn, F Raffi, Juan A. Pineda, Marina B. Klein, Eugenia Negredo, Hernando Knobel, J. Slim, P. Benson, L. Waters, E. Teicher, Linos Vandekerckhove, Craig A. Dietz, Magnus Gisslén, Joel E. Gallant, J. Gathe, P. Shalit, D. Prelutsky, G. Voskuhl, D. Rey, E. Van Wijngaerden, Anthony Mills, Erkki Lathouwers, Carl J. Fichtenbaum, I. Brar, Gordon Crofoot, Veerle Hufkens, I. Santos Gil
Publikováno v:
Antiviral Research
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Antiviral Research, Elsevier Masson, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
ANTIVIRAL RESEARCH
Antiviral Research, 2019, 170, pp.104543. ⟨10.1016/j.antiviral.2019.104543⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Antiviral research, Vol. 170, p. 104543 [1-11] (2019)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017eb51bc97390ae19e12fb2aea5fdc8
http://hdl.handle.net/2445/171213
http://hdl.handle.net/2445/171213
Autor:
Christoph D. Spinner, Cristina Mussini, Eric Y Wong, Donghan Luo, Bruce Rashbaum, Cheryl McDonald, John Jezorwski, Kimberley Brown
Publikováno v:
Open Forum Infectious Diseases
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen approved in Europe and under regulatory review in the United States for the treatment of HIV-1 infection. In the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc0b178e7c0b5a4eb1c6edeb7f1bc3e8
https://mediatum.ub.tum.de/doc/1510474/document.pdf
https://mediatum.ub.tum.de/doc/1510474/document.pdf
Autor:
Margarita Cortés, Betzana Zambrano, Claudio F. Lanata, John Jezorwski, Hector Verastegui, Teresa Andrade, Denis Crevat, Pio López, Isabel Amemiya, Viviana Marquez, Fernando Noriega, Cynthia Terrones, Ana I. Gil
Publikováno v:
The Pediatric infectious disease journal. 35(10)
Dengue and yellow fever (YF) viruses are closely related members of the Flaviviridae family. Given the inherent similarities between the YF vaccine and dengue vaccine (CYD-TDV) candidate, it is possible that the latter could interfere with the respon